everolimus

P2, N=60, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting

TYMS levels also impact the efficacy of everolimus, an FDA-approved mTOR inhibitor for patients with PanNET, underscoring the clinical significance of our findings. In summary, our study uncovers a new role of TYMS linking nucleotide metabolism to growth signaling pathways via the regulation of the AMPK-mTOR axis.

P3, N=240, Active, not recruiting, MedSIR | Recruiting --> Active, not recruiting

P1, N=20, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Initiation date: Sep 2025 --> Dec 2025 | Not yet recruiting --> Recruiting

This study presents a novel and effective strategy to induce the abscopal effect through a synergistic combination of targeted drug delivery, radiotherapy, and immunotherapy. The approach offers strong translational potential for improving radioimmunotherapy outcomes in renal and potentially other immunogenic cancers.

PIP mRNA expression and specific immune-stromal features are associated with resistance to EVE. These findings suggest the potential of PIP as a spatially resolved predictive biomarker for patient stratification in HR+/HER2- ABC.

Daily administration of CPT-11 may have significant antitumor effects based on its anti-angiogenic effects. Daily administration of CPT-11 may be a novel second-line option for SCLC.

Therapeutic options include somatostatin analogs, multi-targeted tyrosine kinase inhibitors (e.g., sunitinib), or mammalian targets of rapamycin (mTOR) inhibitors (e.g., everolimus), telotristat ethyl, chemotherapy, and peptide-receptor radionuclide therapy. Biomarkers may assist in both the diagnosis and post-treatment follow-up in patients with GEP-NETs. The next decade of research on GEP-NETs is promising and should provide new insights into the molecular underpinnings of this disease, therapy selection, and the sequencing of the available therapies, along with the potential role of AL in NET pharmacotherapy.

Moreover, the presence of PFKFB4-ΔEx6 notably sensitized HCC cells to everolimus both in vitro and in subcutaneous models (n = 8, p <0.01)...Given the clinical importance of mTOR/AKT inhibitors, PFKFB4-ΔEx6 could act as a predictive marker for treatment response, paving the way for personalized therapeutic strategies in HCC. These findings provide new insights into the functional diversity of glycolytic enzymes in cancer biology and targeted therapy.

P1, N=45, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Oct 2025 --> Oct 2026

P3, N=2000, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Everolimus is an mammalian target of rapamycin (mTOR) inhibitor used in combination with exemestane for metastatic ER+BC. Combining trametinib with everolimus treatment significantly reduces resistant cell growth. Our results demonstrate that everolimus-resistant ER+BC cells evade therapy via alternate growth-factor signaling linked to activation of SMARCD3 regulons, which can be therapeutically targeted using MEK1/2 inhibitors.